Literature DB >> 33732872

Acute Severe Thrombocytopenia Event Associated with Trimethoprim/Sulfamethoxazole Use.

Andrew V Doodnauth1, Shruthi Sivakumar1, Yohannes Mulatu1, Eilliut Alicea1, Samy I McFarlane1.   

Abstract

OBJECTIVE: To report a case of life-threatening thrombocytopenia associated with the use of trimethoprim/sulfamethoxazole (TMP/SMX) therapy. REPORT OF THE CASE: 50-year-old woman with no significant past medical history who presented with one day of petechial rash on her arms, chest and legs. Patient reports that she had just completed a 7- day course of TMP/SMX (1-double strength tablet twice a day) for uncomplicated UTI by her PMD. On admission, the patient was hemodynamically stable, and complete blood cell count revealed a platelet count of 2000/uL. TMP/SMX was believed to be the most likely cause of thrombocytopenia. After discontinuation of TMP/SMX and treatment with 2 units of platelets, 1gm intravenous immunoglobulin (IVIG) and oral dexamethasone, repeat CBC showed a stable platelet count of 90,000/uL. Patient was successfully discharged on hospital day 3 with outpatient follow up with the hematology clinic for further monitoring. CONCLUSION AND DISCUSSION: Differential diagnosis of severe thrombocytopenia include drug induced thrombocytopenia (DITP), thrombotic thrombocytopenic purpura (TTP), post transfusion purpura (PTP), immune thrombocytopenic purpura (ITP), heparin induced thrombocytopenia (HIT), or catastrophic antiphospholipid antibody syndrome (APS). Drug-dependent antibodies are an unusual class of antibodies that bind firmly to specific epitopes on platelet surface glycoproteins only in the presence of the sensitizing drugs. DITP typically has an abrupt onset of severe thrombocytopenia, usually less than 20,000/uL. Thrombocytopenia usually begins to recover within 1-2 days after the offending drug is discontinued and platelet levels usually normalize within one week as demonstrated in our case report. Pharmacological treatment can include platelet transfusions in case of severe, overt bleeding, corticosteroids or IVIG administration. In most cases, however, discontinuation of the offending drug is sufficient.

Entities:  

Keywords:  adverse drug reaction; bactrim; thrombocytopenia; trimethoprim/sulfamethoxazole

Year:  2021        PMID: 33732872      PMCID: PMC7963350          DOI: 10.12691/ajmcr-9-3-6

Source DB:  PubMed          Journal:  Am J Med Case Rep        ISSN: 2374-2151


  7 in total

Review 1.  Drug-induced immune thrombocytopenia.

Authors:  Richard H Aster; Daniel W Bougie
Journal:  N Engl J Med       Date:  2007-08-09       Impact factor: 91.245

2.  Sulfamethoxazole-induced thrombocytopenia masquerading as posttransfusion purpura: a case report.

Authors:  Christian P Nixon; Tracey A Cheves; Joseph D Sweeney
Journal:  Transfusion       Date:  2015-06-22       Impact factor: 3.157

3.  Trimethoprim-sulfamethoxazole induced rash and fatal hematologic disorders.

Authors:  Zeliha Kocak; Cigdem Ataman Hatipoglu; Gunay Ertem; Sami Kinikli; Abdurrahman Tufan; Hasan Irmak; Ali Pekcan Demiroz
Journal:  J Infect       Date:  2005-07-05       Impact factor: 6.072

4.  Rapid-Onset Thrombocytopenia Following Piperacillin-Tazobactam Reexposure.

Authors:  Van Dong Nguyen; Jean-François Tourigny; Renaud Roy; Denis Brouillette
Journal:  Pharmacotherapy       Date:  2015-12       Impact factor: 4.705

5.  Severe thrombocytopenia possibly associated with TMP/SMX therapy.

Authors:  Weeranuj Yamreudeewong; Brian J Fosnocht; Janice M Weixelman
Journal:  Ann Pharmacother       Date:  2002-01       Impact factor: 3.154

Review 6.  Drug-induced thrombocytopenia: pathogenesis, evaluation, and management.

Authors:  James N George; Richard H Aster
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

7.  Life-Threatening Thrombocytopenia Secondary to Trimethoprim/Sulfamethoxazole.

Authors:  Pramod Gaudel; Ahmed H Qavi; Prasanta Basak
Journal:  Cureus       Date:  2017-12-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.